Tags

Type your tag names separated by a space and hit enter

How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
Circ Heart Fail 2014; 7(3):536CH

Authors+Show Affiliations

From the HRB Clinical Research Facility, National University of Ireland Galway, Galway, Ireland. d.sexton1@nuigalway.ie.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

24847129

Citation

Sexton, Donal J.. "How Should We Modify Recommended Renin-angiotensin-aldosterone System Inhibition when Facing the Cardiorenal Syndrome?" Circulation. Heart Failure, vol. 7, no. 3, 2014, p. 536.
Sexton DJ. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome? Circ Heart Fail. 2014;7(3):536.
Sexton, D. J. (2014). How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome? Circulation. Heart Failure, 7(3), p. 536. doi:10.1161/CIRCHEARTFAILURE.113.000843.
Sexton DJ. How Should We Modify Recommended Renin-angiotensin-aldosterone System Inhibition when Facing the Cardiorenal Syndrome. Circ Heart Fail. 2014;7(3):536. PubMed PMID: 24847129.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome? A1 - Sexton,Donal J, PY - 2014/5/22/entrez PY - 2014/5/23/pubmed PY - 2014/9/18/medline KW - cardio-renal syndrome KW - heart failure SP - 536 EP - 536 JF - Circulation. Heart failure JO - Circ Heart Fail VL - 7 IS - 3 SN - 1941-3297 UR - https://www.unboundmedicine.com/medline/citation/24847129/How_should_we_modify_recommended_renin_angiotensin_aldosterone_system_inhibition_when_facing_the_cardiorenal_syndrome L2 - http://www.ahajournals.org/doi/full/10.1161/CIRCHEARTFAILURE.113.000843?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -